Brief: Sino Biopharmaceutical Says Positive Results From Phase III Study Of Benmelstobart Injection
27/12/2024 01:27
Dec 27 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* BENMELSTOBART INJECTION PRIMARY STUDY ENDPOINT
PROGRESSION-FREE
SURVIVAL MET
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit